161 related articles for article (PubMed ID: 38086859)
21. Zinc metalloregulation of the zinc finger pair domain.
Bird AJ; Swierczek S; Qiao W; Eide DJ; Winge DR
J Biol Chem; 2006 Sep; 281(35):25326-35. PubMed ID: 16829533
[TBL] [Abstract][Full Text] [Related]
22. [Development of novel cereblon modulators and their target molecules].
Ito T
Rinsho Ketsueki; 2022; 63(6):573-579. PubMed ID: 35831190
[TBL] [Abstract][Full Text] [Related]
23. Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs.
Lindner S; Steinebach C; Kehm H; Mangold M; Gütschow M; Krönke J
J Vis Exp; 2019 May; (147):. PubMed ID: 31157769
[TBL] [Abstract][Full Text] [Related]
24. Cereblon modulators: Low molecular weight inducers of protein degradation.
Chamberlain PP; Cathers BE
Drug Discov Today Technol; 2019 Apr; 31():29-34. PubMed ID: 31200856
[TBL] [Abstract][Full Text] [Related]
25. Solution structure of the RNA binding domain in the human muscleblind-like protein 2.
He F; Dang W; Abe C; Tsuda K; Inoue M; Watanabe S; Kobayashi N; Kigawa T; Matsuda T; Yabuki T; Aoki M; Seki E; Harada T; Tomabechi Y; Terada T; Shirouzu M; Tanaka A; Güntert P; Muto Y; Yokoyama S
Protein Sci; 2009 Jan; 18(1):80-91. PubMed ID: 19177353
[TBL] [Abstract][Full Text] [Related]
26. UBE2G1 governs the destruction of cereblon neomorphic substrates.
Lu G; Weng S; Matyskiela M; Zheng X; Fang W; Wood S; Surka C; Mizukoshi R; Lu CC; Mendy D; Jang IS; Wang K; Marella M; Couto S; Cathers B; Carmichael J; Chamberlain P; Rolfe M
Elife; 2018 Sep; 7():. PubMed ID: 30234487
[TBL] [Abstract][Full Text] [Related]
27. Development of BODIPY FL Thalidomide As a High-Affinity Fluorescent Probe for Cereblon in a Time-Resolved Fluorescence Resonance Energy Transfer Assay.
Lin W; Li Y; Min J; Liu J; Yang L; Lee RE; Chen T
Bioconjug Chem; 2020 Nov; 31(11):2564-2575. PubMed ID: 33070611
[TBL] [Abstract][Full Text] [Related]
28. Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome.
Donovan KA; An J; Nowak RP; Yuan JC; Fink EC; Berry BC; Ebert BL; Fischer ES
Elife; 2018 Aug; 7():. PubMed ID: 30067223
[TBL] [Abstract][Full Text] [Related]
29. Development of sulfonyl fluoride chemical probes to advance the discovery of cereblon modulators.
Liu Y; Nowak RP; Che J; Donovan KA; Huerta F; Liu H; Metivier RJ; Fischer ES; Jones LH
RSC Med Chem; 2024 Feb; 15(2):607-611. PubMed ID: 38389883
[TBL] [Abstract][Full Text] [Related]
30. Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders.
Yamamoto J; Ito T; Yamaguchi Y; Handa H
Chem Soc Rev; 2022 Aug; 51(15):6234-6250. PubMed ID: 35796627
[TBL] [Abstract][Full Text] [Related]
31. [Cereblon as a primary target of IMiDs].
Ito T; Handa H
Rinsho Ketsueki; 2019; 60(9):1013-1019. PubMed ID: 31597822
[TBL] [Abstract][Full Text] [Related]
32. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.
Chamberlain PP; Lopez-Girona A; Miller K; Carmel G; Pagarigan B; Chie-Leon B; Rychak E; Corral LG; Ren YJ; Wang M; Riley M; Delker SL; Ito T; Ando H; Mori T; Hirano Y; Handa H; Hakoshima T; Daniel TO; Cathers BE
Nat Struct Mol Biol; 2014 Sep; 21(9):803-9. PubMed ID: 25108355
[TBL] [Abstract][Full Text] [Related]
33. Structural basis of lenalidomide-induced CK1α degradation by the CRL4(CRBN) ubiquitin ligase.
Petzold G; Fischer ES; Thomä NH
Nature; 2016 Apr; 532(7597):127-30. PubMed ID: 26909574
[TBL] [Abstract][Full Text] [Related]
34. Cereblon target validation using a covalent inhibitor of neosubstrate recruitment.
Dann GP; Liu H; Nowak RP; Jones LH
Methods Enzymol; 2023; 681():155-167. PubMed ID: 36764755
[TBL] [Abstract][Full Text] [Related]
35. Role for first zinc finger of WT1 in DNA sequence specificity: Denys-Drash syndrome-associated WT1 mutant in ZF1 enhances affinity for a subset of WT1 binding sites.
Wang D; Horton JR; Zheng Y; Blumenthal RM; Zhang X; Cheng X
Nucleic Acids Res; 2018 May; 46(8):3864-3877. PubMed ID: 29294058
[TBL] [Abstract][Full Text] [Related]
36. A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos.
Matyskiela ME; Zhang W; Man HW; Muller G; Khambatta G; Baculi F; Hickman M; LeBrun L; Pagarigan B; Carmel G; Lu CC; Lu G; Riley M; Satoh Y; Schafer P; Daniel TO; Carmichael J; Cathers BE; Chamberlain PP
J Med Chem; 2018 Jan; 61(2):535-542. PubMed ID: 28425720
[TBL] [Abstract][Full Text] [Related]
37. [Recent topics in IMiDs and cereblon].
Ito T; Handa H
Rinsho Ketsueki; 2017; 58(10):2067-2073. PubMed ID: 28978850
[TBL] [Abstract][Full Text] [Related]
38. Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology.
Ito T; Yamaguchi Y; Handa H
Cell Chem Biol; 2021 Jul; 28(7):987-999. PubMed ID: 34033753
[TBL] [Abstract][Full Text] [Related]
39. From Thalidomide to Rational Molecular Glue Design for Targeted Protein Degradation.
Oleinikovas V; Gainza P; Ryckmans T; Fasching B; Thomä NH
Annu Rev Pharmacol Toxicol; 2024 Jan; 64():291-312. PubMed ID: 37585660
[TBL] [Abstract][Full Text] [Related]
40. Molecular Mechanisms of the Teratogenic Effects of Thalidomide.
Asatsuma-Okumura T; Ito T; Handa H
Pharmaceuticals (Basel); 2020 May; 13(5):. PubMed ID: 32414180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
